NEW DELHI (dpa-AFX) - Pharma major Lupin Ltd. announced Monday that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (EVFM), a U.S. biopharmaceutical company focused exclusively on Women's Health.
Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC (secnidazole) 2g oral granules.
This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News
